Imgatuzumab is a glycoengineered anti-epidermal growth factor receptor (EGFR) monoclonal antibody optimized to induce antibody derived cellular cytotoxicity (ADCC), antibody derived cell phagocytosis (ADCP) and EGFR signal transduction inhibition, while targeting distinct epitopes from Cetuximab. Licensed from Roche, PEGASCY sold it in 2021 to Centessa